Comparison of coagulation factor levels in cryoprecipitate and corresponding fresh frozen plasma
10.13303/j.cjbt.issn.1004-549x.2026.09.018
- VernacularTitle:冷沉淀与新鲜冰冻血浆中凝血因子含量比较
- Author:
Tiantian WANG
1
;
Cuicui QIAO
1
;
Hehe WANG
1
;
Xiyuan WANG
1
;
Jie WANG
1
;
Weidong HE
1
;
Changkui SUN
1
;
Yunhai FANG
1
Author Information
1. Shandong Blood Center, Jinan 250014, China
- Publication Type:Journal Article
- Keywords:
cryoprecipitate;
fresh frozen plasma;
coagulation factors;
von Willebrand factor;
precision transfusion
- From:
Chinese Journal of Blood Transfusion
2026;39(9):1286-1289
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze and compare the levels of various coagulation factors in cryoprecipitate and corresponding fresh frozen plasma, thereby providing a basis for the precise clinical administration of cryoprecipitate. Methods: Fibrinogen, coagulation factors Ⅱ, Ⅴ, Ⅶ, Ⅷ, Ⅸ, Ⅹ, Ⅺ, Ⅻ, and ⅩⅢ, von Willebrand factor antigen (VWF∶Ag), and von Willebrand factor activity (VWF∶Act) were measured in cryoprecipitate and corresponding fresh frozen plasma prepared from 400 mL of whole blood. The levels of each coagulation factor were quantified and subjected to paired comparisons; the total coagulation factor content was also calculated for each bag of cryoprecipitate and fresh frozen plasma. Results: The fibrinogen level in the precipitate was (4.48±0.83) g/L, coagulation factor Ⅷ activity was (330.11±172.00) IU/dL, VWF∶Ag was (510.7±229.34) IU/dL, VWF∶Act was (341.35±116.21) IU/dL; the activities of other coagulation factors did not differ significantly from those in fresh frozen plasma. In each bag of cryoprecipitate (47.7±1.68) mL, the fibrinogen content was (211.94±39.6) mg, the coagulation factor Ⅷ content was (156.67±79.82) IU, the VWF∶Ag content was (245.18±103.25) IU, VWF∶Act was (164.21±54.30) IU. Paired comparisons between cryoprecipitate and fresh frozen plasma revealed that the concentrations of Fib, FⅧ, FⅨ, FⅪ, FⅫ, FⅩⅢ, VWF∶Ag, and VWF∶Act in cryoprecipitate were all higher than those in fresh frozen plasma, with statistically significant differences (P<0.05). Conclusion: Fresh frozen plasma and cryoprecipitate can serve as treatment options for patients with coagulation factor deficiencies. The results provide data to guide the precise selection of blood products and the rational use of blood in clinical practice.
